| Columbine Manor Care Center | |
| 530 W 16th St, Salida, Colorado 81201 | |
| (719) 539-6112 | |
| Name | Columbine Manor Care Center |
|---|---|
| Location | 530 W 16th St, Salida, Colorado |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 112 |
| Occupancy Rate | 42.86% |
| Medicare ID (CCN) | 065220 |
| Legal Business Name | Life Care Centers Of America, Inc. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1467461103 |
| Organization Name | LIFE CARE CENTERS OF AMERICA, INC. |
| Doing Business As | COLUMBINE MANOR CARE CENTER |
| Address | 530 W 16th St, Salida, CO 81201 |
| Phone Number | 719-539-6112 |
News Archive
iBio, Inc. today announced the grant of a commercial, royalty-bearing license to Fiocruz/Bio-Manguinhos of Brazil to develop, manufacture and sell certain vaccines based upon iBio's proprietary technology. Fiocruz/Bio-Manguinhos will invest more than $6 million to bring the first product - a new yellow fever vaccine - through Phase I clinical trials.
An international research team, led by scientists from the German Primate Center, the Robert Koch Institute, the Max Planck Institute for Evolutionary Anthropology, McGill University, Masaryk University, the University of Tübingen and the Max Planck Institute for the Science of Human History, has successfully recovered genomes of the bacterium Treponema pallidum, which causes syphilis and yaws in humans, from wild nonhuman primate populations across sub-Saharan Africa.
A federal judge's recent ruling blocking Medicaid officials from cutting off a struggling nursing home could help troubled health care facilities survive using bankruptcy, according to restructuring professionals.
AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target.
UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
iBio, Inc. today announced the grant of a commercial, royalty-bearing license to Fiocruz/Bio-Manguinhos of Brazil to develop, manufacture and sell certain vaccines based upon iBio's proprietary technology. Fiocruz/Bio-Manguinhos will invest more than $6 million to bring the first product - a new yellow fever vaccine - through Phase I clinical trials.
An international research team, led by scientists from the German Primate Center, the Robert Koch Institute, the Max Planck Institute for Evolutionary Anthropology, McGill University, Masaryk University, the University of Tübingen and the Max Planck Institute for the Science of Human History, has successfully recovered genomes of the bacterium Treponema pallidum, which causes syphilis and yaws in humans, from wild nonhuman primate populations across sub-Saharan Africa.
A federal judge's recent ruling blocking Medicaid officials from cutting off a struggling nursing home could help troubled health care facilities survive using bankruptcy, according to restructuring professionals.
AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target.
UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $650 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 15.79 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.06 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 54.84 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 3.13 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.17 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 88.54 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 0.52 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 78.67 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 21.1 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 7.85 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 1.57 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 89.77 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 75.1 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 78.03 | 82.93 |
News Archive
iBio, Inc. today announced the grant of a commercial, royalty-bearing license to Fiocruz/Bio-Manguinhos of Brazil to develop, manufacture and sell certain vaccines based upon iBio's proprietary technology. Fiocruz/Bio-Manguinhos will invest more than $6 million to bring the first product - a new yellow fever vaccine - through Phase I clinical trials.
An international research team, led by scientists from the German Primate Center, the Robert Koch Institute, the Max Planck Institute for Evolutionary Anthropology, McGill University, Masaryk University, the University of Tübingen and the Max Planck Institute for the Science of Human History, has successfully recovered genomes of the bacterium Treponema pallidum, which causes syphilis and yaws in humans, from wild nonhuman primate populations across sub-Saharan Africa.
A federal judge's recent ruling blocking Medicaid officials from cutting off a struggling nursing home could help troubled health care facilities survive using bankruptcy, according to restructuring professionals.
AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target.
UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.
› Verified 7 days ago